PTC Therapeutics (NASDAQ:PTCT) Insider Neil Gregory Almstead Sells 881 Shares of Stock
Multiple PTC Therapeutics executives sold shares at mid-$70 prices between Jan 6–12, amid strong earnings showing 7.2% revenue growth, according to SEC filings.
4 Articles
4 Articles
PTC Therapeutics (NASDAQ:PTCT) CAO Christine Marie Utter Sells 1,034 Shares
PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) CAO Christine Marie Utter sold 1,034 shares of the company’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $76.45, for a total value of $79,049.30. Following the sale, the chief accounting officer owned 72,693 shares of the company’s stock, valued at approximately $5,557,379.85. This represents a 1.40% decrease in their ownership of the stock. The…
Camden Property Trust (NYSE:CPT) Price Target Raised to $120.00
Camden Property Trust (NYSE:CPT – Free Report) had its target price lifted by Mizuho from $114.00 to $120.00 in a report issued on Monday morning, MarketBeat Ratings reports. The brokerage currently has an outperform rating on the real estate investment trust’s stock. Several other research analysts have also weighed in on CPT. Wells Fargo & […]
AbCellera Biologics (NASDAQ:ABCL) Shares Down 5.6% – Should You Sell?
AbCellera Biologics Inc. (NASDAQ:ABCL – Get Free Report) shares traded down 5.6% during mid-day trading on Tuesday . The stock traded as low as $4.08 and last traded at $4.2650. 2,665,212 shares were traded during trading, a decline of 45% from the average session volume of 4,846,393 shares. The stock had previously closed at $4.52. […]
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium